Freenome Holdings Inc.
Freenome is a biotechnology company dedicated to early cancer detection through a comprehensive multiomics platform that uses a standard blood draw. Combining molecular biology, computational biology, and machine learning, Freenome develops noninvasive blood tests to detect cancer at its earliest, most treatable stages, aiming to make cancer screening accessible and effective for everyone.
Industries
Nr. of Employees
large (251-1000)
Freenome Holdings Inc.
Patents
Machine learning implementation for multi-analyte assay development and testing
US-11847532-B2
View DetailsMachine learning implementation for multi-analyte assay development and testing
US-11681953-B2
View Details
Machine learning implementation for multi-analyte assay development and testing
US-11847532-B2
View DetailsMachine learning implementation for multi-analyte assay development and testing
US-11681953-B2
View DetailsProducts
Blood-based colorectal cancer screening test (multiomics, regulatory submission in progress)
A multiomics blood test combining genomic, epigenomic, and proteomic signals with machine learning to detect colorectal cancer and high-risk lesions from a standard blood draw; performance validated in a large prospective registrational study and published in a peer-reviewed journal.
Autoantibody-based lung cancer blood test (CE‑IVD marked, acquired capability)
A CE‑IVD–marked blood-based autoantibody assay used for lung cancer detection and to aid risk stratification in targeted screening programs; acquisition provides access to an established autoantibody discovery platform and commercial assay experience.
Blood-based colorectal cancer screening test (multiomics, regulatory submission in progress)
A multiomics blood test combining genomic, epigenomic, and proteomic signals with machine learning to detect colorectal cancer and high-risk lesions from a standard blood draw; performance validated in a large prospective registrational study and published in a peer-reviewed journal.
Autoantibody-based lung cancer blood test (CE‑IVD marked, acquired capability)
A CE‑IVD–marked blood-based autoantibody assay used for lung cancer detection and to aid risk stratification in targeted screening programs; acquisition provides access to an established autoantibody discovery platform and commercial assay experience.
Services
Collaborative programs to identify and validate molecular and protein biomarkers for diagnostic and drug-response applications with pharmaceutical and academic partners.
Design and operationalization of large-scale prospective clinical trials with hybrid recruitment and site networks to validate blood-based screening tests.
Solutions that combine multiomic testing with real-world clinical data and electronic medical record integration to support population-health workflows and care-pathway optimization.
Development and deployment of AI models for diagnostic classification using multiomic datasets and feedback loops from clinical data.
Collaborative programs to identify and validate molecular and protein biomarkers for diagnostic and drug-response applications with pharmaceutical and academic partners.
Design and operationalization of large-scale prospective clinical trials with hybrid recruitment and site networks to validate blood-based screening tests.
Solutions that combine multiomic testing with real-world clinical data and electronic medical record integration to support population-health workflows and care-pathway optimization.
Development and deployment of AI models for diagnostic classification using multiomic datasets and feedback loops from clinical data.
Expertise Areas
- Early cancer detection using blood-based assays
- Multiomics profiling and integration
- Machine learning for diagnostics and biomarker discovery
- Clinical trial design and registrational study execution
Key Technologies
- Cell-free DNA sequencing
- Methylation profiling
- Proteomics / quantitative protein assays
- Autoantibody profiling
News & Updates
Freenome's acquisition of Oncimmune Ltd enhances its product portfolio, including an autoantibody platform with additional biomarkers important in cancer detection, and accelerates its path to clinical impact in new indications.
Freenome's study demonstrated high sensitivity and specificity for early-stage colorectal cancer, with results published in JAMA.
Freenome secured significant funding to expand its platform and advance its blood-based cancer detection tests.
Freenome and Merck KGaA announced a study demonstrating the combination of multiomics profiling and computational modeling in non-small cell lung cancer detection.
Freenome's pivotal study for colorectal cancer detection showed high sensitivity and specificity, with results published in JAMA.
Freenome's PREEMPT CRC study enrolled over 35,000 participants and validated its blood test for early colorectal cancer detection.
Freenome's acquisition of Oncimmune Ltd enhances its product portfolio, including an autoantibody platform with additional biomarkers important in cancer detection, and accelerates its path to clinical impact in new indications.
Freenome's study demonstrated high sensitivity and specificity for early-stage colorectal cancer, with results published in JAMA.
Freenome secured significant funding to expand its platform and advance its blood-based cancer detection tests.
Freenome and Merck KGaA announced a study demonstrating the combination of multiomics profiling and computational modeling in non-small cell lung cancer detection.
Freenome's pivotal study for colorectal cancer detection showed high sensitivity and specificity, with results published in JAMA.
Freenome's PREEMPT CRC study enrolled over 35,000 participants and validated its blood test for early colorectal cancer detection.